The FDA has granted an approval to the combination of atezolizumab (Tecentriq) with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).1
"Tecentriq is the first cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer, which is especially difficult to treat," said Sandra Horning, MD, chief medical officer and head of Global Product Development, Genentech (Roche), the manufacturer of the PD-L1 inhibitor. "Until now, there have been limited treatment advances for this disease, and we are excited to bring a potential new standard of care to patients that has been shown to improve survival compared to chemotherapy."
Data showed that after a median follow-up of 13.9 months, the median OS in IMpower133 was 12.3 months (95% CI, 10.8-15.9) in the atezolizumab arm compared with 10.3 months (95% CI, 9.3-11.3) in the carboplatin/etoposide and placebo arm, leading to a 30% reduction in the risk of death (HR, 0.70; 95% CI, 0.54-0.91; P = .0069).
... to read the full story